[Editor’s note: Due to a technical glitch, some readers may not have been able to access this article when it was first published on 27 May. We now republish it in full.] A Cochrane review of the evidence has confirmed capecitabine has a moderate benefit in hormone receptor‐positive metastatic breast cancer but found no benefit ...
Capecitabine differentially helpful based on HR status
By Mardi Chapman
27 May 2021